文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

重组活化蛋白C对LPS诱导的mESC来源心肌细胞单层机械顺应性与搏动频率的影响

Recombinant Activated Protein C (rhAPC) Affects Lipopolysaccharide-Induced Mechanical Compliance Changes and Beat Frequency of mESC-Derived Cardiomyocyte Monolayers.
PubMed 文献 · Shock · 2022-01-01
一句话结论体外脓毒症模型显示rhAPC可部分逆转LPS所致心肌细胞机械顺应性升高和搏动频率下降,尚属实验研究。

该研究用小鼠胚胎干细胞来源心肌细胞(mESC-CM)结合CellDrum技术建立LPS(5 μg/mL)体外脓毒症模型,同步测量机械顺应性与搏动频率。LPS 12小时使ROS升高、肌动蛋白应力纤维密度下降、EPCR与PAR1分别下调至0.26与0.39倍,搏动频率在6小时降至86%、12小时降至73%,机械顺应性随时间升高至对照的8倍。给予rhAPC(5 μg/mL,12小时)后ROS降低、肌动蛋白密度恢复、EPCR与PAR1分别上调至4.79与3.49倍,搏动频率在6小时LPS组提高127%、12小时LPS组提高123%,12小时LPS组机械顺应性降低68%。

要点

  • LPS 5 μg/mL作用12小时使mESC-CM单层机械顺应性升高至对照8倍,提示脓毒症心肌细胞机械松弛异常。
  • LPS 6小时搏动频率降至86%、12小时降至73%,rhAPC可使6小时LPS组提高127%、12小时LPS组提高123%。
  • LPS 12小时使EPCR与PAR1分别下调至0.26与0.39倍,rhAPC后分别上调至4.79与3.49倍。
  • rhAPC 5 μg/mL、12小时使12小时LPS损伤组的机械顺应性降低68%,并降低ROS、恢复肌动蛋白应力纤维密度。
  • 以上均为mESC-CM体外模型结果,不能直接外推为脓毒症心肌病患者的临床用药推荐。

适用人群与场景

  • 体外小鼠胚胎干细胞来源心肌细胞(mESC-CM)单层,LPS 5 μg/mL诱导的体外脓毒症模型;非患者人群。

诊断标准与关键阈值

  • 体外脓毒症模型:LPS 5 μg/mL孵育mESC-CM 6小时或12小时。
  • 检测指标:CellDrum技术测机械顺应性与搏动频率;ROS可视化、肌动蛋白应力纤维、EPCR与PAR1 mRNA定量。

处置流程与药物剂量

  • 第一步:mESC-CM单层接受LPS 5 μg/mL孵育6小时或12小时建立损伤模型。
  • 第二步:给予人重组活化蛋白C(rhAPC)5 μg/mL、12小时,可单独或与LPS predamage联合应用。
  • 原文未提及临床给药途径、频次、疗程或目标值。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型为体外细胞实验,非临床研究;样本量与中心数原文未提及。
  • LPS 5 μg/mL 12小时使ROS升高、肌动蛋白应力纤维密度下降,EPCR与PAR1分别显著下调至0.26与0.39倍(对照)。
  • 搏动频率在LPS 6小时降至86%、12小时降至73%;机械顺应性随时间升高,12小时达对照8倍。
  • rhAPC 5 μg/mL 12小时使ROS降低、肌动蛋白密度恢复,EPCR与PAR1分别显著上调至4.79与3.49倍(LPS predamage组)。
  • rhAPC使搏动频率提高127%(6h-LPS组)与123%(12h-LPS组),使12h-LPS组机械顺应性降低68%。

证据类型、等级与局限

  • 证据类型:体外细胞实验(非RCT、非队列);原文未给出证据等级或推荐强度。
  • 局限:仅为mESC-CM体外模型,物种与细胞来源不同于人;样本量原文未提及;结果需进一步验证。

对床旁实践的改变

  • 该内容为体外机制研究,不能据此在急诊或ICU对脓毒症心肌病患者使用rhAPC。
  • 可提示脓毒症心肌病中EPCR/PAR1通路与心肌细胞机械功能相关,但尚不能转化为床旁决策。
  • 原文未提及适用或不适用人群、常见陷阱。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Septic cardiomyopathy increases mortality by 70% to 90% and results in mechanical dysfunction of cells.

METHODS: Here, we created a LPS-induced in-vitro sepsis model with mouse embryonic stem cell-derived cardiomyocytes (mESC-CM) using the CellDrum technology which simultaneously measures mechanical compliance and beat frequency of mESCs. Visualization of reactive oxygen species (ROS), actin stress fibers, and mRNA quantification of endothelial protein C receptor (EPCR) and protease-activated receptor 1 (PAR1) before/after LPS incubation were used for method validation. Since activated protein C (APC) has cardioprotective effects, samples were treated with human recombinant APC (rhAPC) with/-out LPS predamage to demonstrate the application in therapeutic studies.

RESULTS: Twelve hours LPS treatment (5 μg/mL) increased ROS and decreased actin stress fiber density and significantly downregulated EPCR and PAR1 compared to control samples (0.26, 0.39-fold respectively). rhAPC application (5 μg/mL, 12 h) decreased ROS and recovered actin density, EPCR, and PAR1 levels were significantly upregulated compared to LPS predamaged samples (4.79, 3.49-fold respectively). The beat frequencies were significantly decreased after 6- (86%) and 12 h (73%) of LPS application. Mechanical compliance of monolayers significantly increased in a time-dependent manner, up to eight times upon 12-h LPS incubation compared to controls. rhAPC incubation increased the beat frequency by 127% (6h-LPS) and 123% (12h-LPS) and decreased mechanical compliance by 68% (12h-LPS) compared to LPS predamaged samples.

CONCLUSION: LPS-induced contraction dysfunction and the reversal effects of rhAPC were successfully assessed by the mechanical properties of mESC-CMs. The CellDrum technology proved a decent tool to simulate sepsis in-vitro.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Temiz Artmann A, Kurulgan Demirci E, Fırat IS, et al. Recombinant Activated Protein C (rhAPC) Affects Lipopolysaccharide-Induced Mechanical Compliance Changes and Beat Frequency of mESC-Derived Cardiomyocyte Monolayers. Shock. 2022. PMID: 34416756. doi:10.1097/SHK.0000000000001845

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。